A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess The Efficacy, Safety, And Tolerability Of PF-03715455 Administered Twice Daily By Inhalation For 12 Weeks In Subjects With Persistent Moderate To Severe Asthma Who Remain Uncontrolled Despite Treatment With Inhaled Corticosteroids (ICS) And Long-Acting Beta2 Agonists (LABA)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess The Efficacy, Safety, And Tolerability Of PF-03715455 Administered Twice Daily By Inhalation For 12 Weeks In Subjects With Persistent Moderate To Severe Asthma Who Remain Uncontrolled Despite Treatment With Inhaled Corticosteroids (ICS) And Long-Acting Beta2 Agonists (LABA)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs PF 3715455 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Oct 2015 According to ClinicalTrials.gov, this study was terminated because of business reasons. No safety or efficacy concerns contributed to the termination of the study.
    • 25 Sep 2015 Status changed from completed to discontinued as per ClinicalTrials.gov.
    • 31 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top